1
项与 Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein(Fred Hutchinson Cancer Research Center) 相关的临床试验Evaluation of Pretargeted Anti-CD20 Radioimmunotherapy Combined With BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk B-Cell Malignancies
This phase I/II trial studies the side effects and best dose of anti-cluster of differentiation (CD)20 radioimmunotherapy (RIT), and to see how well it works when given before chemotherapy and stem cell transplant in treating patients with B-cell malignancies that have not responded to treatment or have come back after responding to treatment. CD20 is a protein found on the cells of a type of cancer cell called B-cells. Anti-CD20 RIT attaches radioactive material to a drug that is designed to target CD20, which brings radioactive material to the cancer cells to kill the cells. This may kill more tumor cells while causing fewer side effects to healthy tissue. Adding anti-CD20 to standard chemotherapy and stem cell transplant may be more effective in treating patients with B-cell malignancies.
100 项与 Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein(Fred Hutchinson Cancer Research Center) 相关的临床结果
100 项与 Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein(Fred Hutchinson Cancer Research Center) 相关的转化医学
100 项与 Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein(Fred Hutchinson Cancer Research Center) 相关的专利(医药)
100 项与 Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein(Fred Hutchinson Cancer Research Center) 相关的药物交易